IP Library Granted Patent US 7,622,477
Granted Patent B2
US 7,622,477 · App. 11/364,448 · Granted Nov 24, 2009

Isomers and 42-epimers of rapamycin alkyl ether analogs, methods of making and using the same

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,622,477
App. No.
11/364,448
Granted
Nov 24, 2009
Kind
B2
Abstract

Isomers and 42-epimers of rapamycin alkyl ether analogs and pharmaceutically acceptable salts or prodrugs thereof, are immunomodulatory agents and are useful in the treatment of restenosis and immune and autoimmune diseases. Also disclosed are cancer-, fungal growth-, restenosis-, post-transplant tissue rejection- and immune- and autoimmune disease-inhibiting compositions and a method of inhibiting cancer, fungal growth, restenosis, post-transplant tissue rejection, and immune and autoimmune disease in a mammal. One particular preferred application of such isomers and 42-epimers of rapamycin alkyl ether analogs is in medicated devices and local vascular delivery wherein the stability and lipid solubility and subsequently diffusion through tissue and cell membranes are essential to the success of rapamycin containing combination devices.

Claims (4)

1. A compound having the following structure:

where R is alkyl, alkenyl, alkynyl, aryl, arylalkyl, hydroxyarylalkyl, hydroxyalkyl, dihydroxyalkyl, hydroxyalkoxyalkyl, hydroxyalkylarylalkyl, dihydroxyalkylarylalkyl, alkylcarbonyloxyalkyl, aminoalkyl, alkylaminoalkyl, alkoxycarbonylaminoalkyl, alkylcarbonylaminoalkyl, arylsulfonamidoalkyl, allyl, dihydroxyalkylallyl, dioxolanylallyl, carbalkoxyalkyl, or alkylsilyl;

or a pharmaceutically acceptable salt thereof.

2. A method of inhibiting the neointimal growth of vasculature after catheter and balloon intervention in a mammal, which comprises administering to the mammal an effective amount of any of the compounds of any of claim 1 .

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 13, 2007
From: CORDIS CORPORATION
To: WYETH
Reel/Frame 020234/0460 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 31, 2007
From: ZHAO, JONATHON Z.
To: CORDIS CORPORATION
Reel/Frame 018829/0993 →